AbbVie may now consider a takeover of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), a $411 million company, to expand in that market, Redmond said. Shares of Achillion rallied (ACHN:US) as much as 67 percent yesterday. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was 47.57% in last session and finished the day at $4.25. Traded volume was 47.79million shares in the last session and the average volume of the stock remained 1.42million shares. The beta of the stock remained 1.89. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) insider ownership is 13.04%.

Merck & Co has agreed to buy Idenix Pharmaceuticals Inc (NASDAQ:IDIX) for $3.85bn in a deal aimed at bolstering its position in the hotly contested race to develop a new generation of hepatitis C treatments. The US drugmaker is vying with rivals including Gilead Sciences, Johnson & Johnson and AbbVie for share of a market forecast to reach at least $20bn of annual sales by the end of this decade. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) rose 229.05 percent to $23.79 Monday on volume of 41.11million shares. The intra-day range of the stock was $23.530 to $24.21. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) has a market capitalization of $3.59billion.

Roth Capital lifted their price target on shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to $15.50 in a research note issued on Monday. The firm currently has a “buy” rating on the stock. Roth Capital’s price target suggests a potential upside of 55.00% from the company’s current price. BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s stock on June 09, 2014 reported a decrease of -1.50% to the closing price of $9.85. Its fifty two weeks range is $3.86 -$10.35. The total market capitalization recorded $477.46million. The overall volume in the last trading session was 3.18million shares. In its share capital, BDSI has 48.44million outstanding shares.

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) on June 1 announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago. When overall survival (OS) and progression-free survival (PFS) were assessed in pre-specified patient subgroups, results favored treatment with ICT-107 over control in HLA-A2 patients within each of the two major MGMT subgroups (unmethylated and methylated). On Monday, shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) dropped -1.67% to close the day at $1.18. Company monthly performance is recorded as 5.36%. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) quarterly revenue growth is -9.92%.

Analysts at Singular Research upped their price target on shares of Anika Therapeutics, Inc (NASDAQ:ANIK) from $43.50 to $54.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock. Singular Research’s price target would indicate a potential upside of 15.14% from the stock’s previous close. Anika Therapeutics, Inc. (NASDAQ:ANIK) stock performance was 2.15% in last session and finished the day at $48.86. Traded volume was 1.33million shares in the last session and the average volume of the stock remained 344.38K shares. The beta of the stock remained 1.79. Anika Therapeutics, Inc. (NASDAQ:ANIK) insider ownership is 2.30%.